EUCTR2020-002220-37-IT进行中（未招募）1 期
Comparison of the analgesic effect of a new paracetamol formulation (paracetamol UNIFLASH) for buccal use and two different doses of an oral paracetamol form controlled versus placebo in patients suffering from moderate pain due to a tooth extraction. - Paramouth
ITHER PHARMACEUTICALS0 个研究点目标入组 404 人开始时间: 2021年6月7日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 404
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patient aged from 18 years of age at the time of signing the informed consent;
- •2. Patient scheduled to undergo the removal of one third soft-tissue impacted or not-impacted mandibular molar (associated or not to an ipsilateral erupted maxillary molar) under short-acting local anaesthetic (e.g., mepivacaine or lidocaine) preoperatively;
- •3. Patient weighing > 50 kg;
- •4. Female patient of childbearing potential must be willing to use a highly efficient birth control method during the study;
- •A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- •The following are considered as highly effective birth control methods:
- •Established use of oral, intravaginal or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation - Established use of oral, injected, or implanted progestogen-only hormonal contraception associated with inhibition of ovulation – Intrauterine hormone-releasing system or placement of an intrauterine device – Bilateral tubal occlusion – Vasectomised partner - True abstinence [periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception].
- •5. Patient able to understand and comply with protocol requirements and instructions;
- •6. Patient covered by national healthcare insurance system or similar system, if applicable by local regulations;
- •7. Patient who has signed a written informed consent obtained prior to any study-related procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •1. Patient who undergoes an extraction of contralateral molar in the same procedure or a bony-impacted molar;
- •2. Patient treated by analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) within the 3 days prior to the day of randomization (or within 5 times the elimination half-life whichever the longest);
- •3. Patient who received other analgesic than short-acting preoperative or intraoperative local anaesthetic agents within 12 hours before the start of the surgery or peri-operatively until randomization;
- •4. Patient with any known hypersensitivity to paracetamol, ibuprofen or ingredients contained in Investigational Medicinal Products (IMP) and Non-Investigational Medicinal Products (NIMP);
- •5. Patient with contra-indication to the alcoholic solution for medical reason (alcoholic weaning or abuse, epilepsy);
- •6. Women with positive results on a urine pregnancy test or breastfeeding women or women of childbearing potential without an effective contraception;
- •7. Patient with current or chronic history of liver disease, or known hepatic or biliary abnormalities;
- •8. Patient with a current or chronic history of severe renal impairment;
- •9. Patient with severe heart failure (New York Heart Association (NYHA) Class IV);
- •10. Patient with history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy;
- •11. Patient with gastrointestinal haemorrhage, cerebrovascular haemorrhage or of other evolving haemorrhage;
- •12. Patient with an active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding);
- •13. Patient with inflammation or ulcerative disease of the oral mucosa (i.e., aphthae…);
- •14. Patient with known systemic lupus erythematosus;
- •15. Patient having developed hypersensitivity reactions, including symptoms of asthma, rhinitis, angioedema or urticaria after taking acetylsalicylic acid or other NSAIDs;
- •16. Patient with drug or alcohol abuse within 6 months before dosing with study medication; Alcohol abuse is defined as the consumption of more than 90 mL of liquor or spirits or 530 mL of beer per day, for 5 consecutive days during the 6-month period. Drug abuse is defined as the use of any recreational drug for 5 consecutive days during the 6-month period.
- •17. Patient having participated in any clinical research study within the previous 30 days or 5 half-lives duration of the biological effect of the investigational product (whichever is longer);
- •18. Patient having any current dental or medical condition that could prevent safe participation in this study;
- •19. Unwillingness or inability to follow the procedures outlined in the protocol.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the efficacy of a new paracetamol formulation for buccal use after a single dose in patients with a moderate pain after a wisdom tooth extraction.Symptomatic short-term treatment of moderate painEUCTR2020-002220-37-FRITHER Pharmaceuticals404
尚未招募
不适用
ovel Herbal Enema of Versus Reference Standard Dashamula Taila Enema in the pain managementCTRI/2022/12/048239il
进行中（未招募）
不适用
A comparison of the analgesic efficacy of pericapsular nerve group blocking vs periarticular injection after total hip arthroplaslty - Prospective studyKCT0006049Chungnam National University Hospital60
已完成
3 期
Paracetamol UNIFLASH for Buccal Use Phase III Trial in Acute Pain Due to a Tooth ExtractionAcute PainNCT04640376Unither Pharmaceuticals, France407
招募中
3 期
Analgesic effect of pericapsular nerve and fascia iliaca block in hip fractureIRCT20170516033992N8Oroumia University of Medical Sciences40